COVID-19 and fungal infection: the need for a strategic approach.
作者信息
White P Lewis, Dhillon Rishi, Hughes Harriet, Wise Matthew P, Backx Matthijs
机构信息
Public Health Wales Microbiology, University Hospital of Wales, Cardiff, CF14 4XW.
Intensive Care Medicine, University Hospital of Wales, Cardiff, CF14 4XW.
出版信息
Lancet Microbe. 2020 Sep;1(5):e196. doi: 10.1016/S2666-5247(20)30127-0. Epub 2020 Sep 7.
Abstract
摘要
相似文献
1
COVID-19 and fungal infection: the need for a strategic approach.
Lancet Microbe. 2020 Sep;1(5):e196. doi: 10.1016/S2666-5247(20)30127-0. Epub 2020 Sep 7.
2
Fungal superinfection in patients with COVID-19: Role of antifungal stewardship?
Am J Infect Control. 2021 Feb;49(2):279-280. doi: 10.1016/j.ajic.2020.11.015. Epub 2020 Nov 19.
3
Mycotic infection prevalence among patients undergoing bronchoalveolar lavage with search of SARS-CoV-2 after two negative nasopharyngeal swabs.
J Breath Res. 2021 Sep 13;15(4). doi: 10.1088/1752-7163/ac2290.
4
Evaluation of superinfection, antimicrobial usage, and airway microbiome with metagenomic sequencing in COVID-19 patients: A cohort study in Shanghai.
J Microbiol Immunol Infect. 2021 Oct;54(5):808-815. doi: 10.1016/j.jmii.2021.03.015. Epub 2021 Apr 6.
5
Dynamics of SARS-CoV2 Infection and Multi-Drug Resistant Bacteria Superinfection in Patients With Assisted Mechanical Ventilation.
Front Cell Infect Microbiol. 2021 Aug 12;11:683409. doi: 10.3389/fcimb.2021.683409. eCollection 2021.
6
COVID-19 and mucormycosis superinfection: the perfect storm.
Infection. 2021 Oct;49(5):833-853. doi: 10.1007/s15010-021-01670-1. Epub 2021 Jul 24.
7
Bacterial and fungal coinfection among hospitalized patients with COVID-19: a retrospective cohort study in a UK secondary-care setting.
Clin Microbiol Infect. 2020 Oct;26(10):1395-1399. doi: 10.1016/j.cmi.2020.06.025. Epub 2020 Jun 27.
8
Respiratory co-and superinfections in COVID-19.
Rev Esp Quimioter. 2021 Sep;34 Suppl 1(Suppl1):69-71. doi: 10.37201/req/s01.20.2021. Epub 2021 Sep 30.
9
Response to the Letter to the Editor on "Bacterial and fungal superinfections are detected at higher frequency in critically ill patients affected by SARS-CoV-2 infection than negative patients and are associated to a worse outcome".
J Med Virol. 2023 Oct;95(10):e29192. doi: 10.1002/jmv.29192.
10
Seek and Ye Shall Find: COVID-19 and Bacterial Superinfection.
Am J Respir Crit Care Med. 2021 Oct 15;204(8):875-877. doi: 10.1164/rccm.202107-1790ED.
引用本文的文献
1
Plasma concentration of voriconazole under concomitant use of nirmatrelvir/ritonavir in patients with COVID-19: a multicenter retrospective study.
Front Pharmacol. 2025 Aug 15;16:1654671. doi: 10.3389/fphar.2025.1654671. eCollection 2025.
2
COVID-19 beyond DAD: Persisting microcirculation thrombosis, hidden infections, and early pulmonary fibrosis as remaining challenges of the disease.
Hum Pathol Rep. 2022 Mar;27:300607. doi: 10.1016/j.hpr.2022.300607. Epub 2022 Feb 28.
3
Design, Synthesis, and Biological Evaluation of '-Phenylhydrazides as Potential Antifungal Agents.
Int J Mol Sci. 2023 Oct 12;24(20):15120. doi: 10.3390/ijms242015120.
4
Homobifunctional imidoester-modified zinc nano-spindle attenuated hyphae growth of against hypersensitivity responses.
iScience. 2023 Jan 11;26(2):105922. doi: 10.1016/j.isci.2022.105922. eCollection 2023 Feb 17.
5
Ayurveda management of pulmonary mycosis: an integrative approach: a case report.
J Med Case Rep. 2023 Feb 8;17(1):48. doi: 10.1186/s13256-022-03736-6.
6
First trend analysis of antifungals consumption in Lebanon using the World Health Organization collaborating center for drug statistics methodology.
BMC Infect Dis. 2022 Nov 24;22(1):882. doi: 10.1186/s12879-022-07883-5.
7
Design, Synthesis and Antifungal Evaluation of Novel Pyrylium Salt In Vitro and In Vivo.
Molecules. 2022 Jul 12;27(14):4450. doi: 10.3390/molecules27144450.
8
Adjunctive use of saturated solution of potassium iodide (SSKI) with liposomal amphotericin B (L-AMB) in mucormycosis achieves favorable response, shortened dose and duration of amphotericin: A retrospective study from a COVID-19 tertiary care center.
Am J Otolaryngol. 2022 May-Jun;43(3):103465. doi: 10.1016/j.amjoto.2022.103465. Epub 2022 Apr 8.
9
COVID-19-Associated Invasive Pulmonary Aspergillosis in the Intensive Care Unit: A Case Series in a Portuguese Hospital.
J Fungi (Basel). 2021 Oct 19;7(10):881. doi: 10.3390/jof7100881.
10
Practice Guidelines for the Diagnosis of COVID-19-Associated Pulmonary Aspergillosis in an Intensive Care Setting.
J Intensive Care Med. 2022 Aug;37(8):985-997. doi: 10.1177/08850666211047166. Epub 2021 Oct 22.
本文引用的文献
1
A National Strategy to Diagnose Coronavirus Disease 2019-Associated Invasive Fungal Disease in the Intensive Care Unit.
Clin Infect Dis. 2021 Oct 5;73(7):e1634-e1644. doi: 10.1093/cid/ciaa1298.
2
COVID-19 and fungal superinfection.
Lancet Microbe. 2020 Jul;1(3):e107. doi: 10.1016/S2666-5247(20)30065-3. Epub 2020 Jul 3.
3
Confronting and mitigating the risk of COVID-19 associated pulmonary aspergillosis.
Eur Respir J. 2020 Oct 1;56(4). doi: 10.1183/13993003.02554-2020. Print 2020 Oct.
4
Invasive fungal diseases during COVID-19: We should be prepared.
J Mycol Med. 2020 Jun;30(2):100971. doi: 10.1016/j.mycmed.2020.100971. Epub 2020 Apr 6.
5
Antifungal therapy decreases sensitivity of the Aspergillus galactomannan enzyme immunoassay.
Clin Infect Dis. 2005 Jun 15;40(12):1762-9. doi: 10.1086/429921. Epub 2005 May 5.
Zotero 插件